Quantcast

Latest Ciprofloxacin Stories

2008-11-05 18:00:22

SALVAT announced today the submission of the response to the FDA Approvable Letter for CETRAXAL(R) (Ciprofloxacin 0.2% Otic Solution in Single Dose Containers). In an Approvable Letter received on April 6, 2006, the FDA requested additional data with respect to chemistry, manufacturing, and controls (CMC). SALVAT expects the FDA to classify the complete response as a Class 2 resubmission, under which the FDA will seek to complete its review of the resubmission within 180 days from the...

2008-10-27 12:00:10

WASHINGTON, Oct. 27 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), today announced new study results that demonstrate doripenem (DORIBAX(TM), doripenem for injection), a carbapenem antibiotic, was found to be more potent in vitro against certain strains of Enterobacteriaceae, including Extended-spectrum Beta-lactamases (ESBLs) than other commonly used carbapenems. Enterobacteriaceae is a large group of bacteria that can cause...

2008-10-23 06:00:11

Aradigm Corporation (OTCBB: ARDM) ("Aradigm") today announced it is presenting data from its Phase 2 study of inhaled liposomal ciprofloxacin (ARD-3100) in cystic fibrosis (CF) patients at the 22nd Annual North American Cystic Fibrosis (NACF) conference in Orlando, Florida. Completed in June 2008, the study was an open-label, two week efficacy and safety trial of once daily inhaled liposomal ciprofloxacin in 22 CF patients conducted at leading CF centers in Australia and New Zealand....

2008-10-16 06:00:31

Depomed, Inc. (NASDAQ:DEPO) today announced that it will release third quarter financial results for 2008 after the market closes on Thursday, October 30, 2008. The company will webcast a conference call beginning at 5:00 p.m. ET, 2:00 p.m. PT to discuss its results and to provide an update and future outlook on company events. Interested parties can access the live and archived broadcast of the call at www.depomedinc.com. About Depomed Depomed, Inc. is a specialty...

2008-10-15 03:00:22

Aradigm has completed enrollment in its Phase II clinical trial of its inhaled liposomal ciprofloxacin in adult patients with non-cystic fibrosis bronchiectasis. The study was initiated in July 2008 in bronchiectasis centers in the UK and enrolled a total of 36 patients as planned. The subjects were randomized to two different dose levels of once-daily inhaled liposomal ciprofloxacin in a parallel design for a treatment period of 28 consecutive days. The primary efficacy endpoint in the...

2008-10-14 06:00:16

Aradigm Corporation (OTCBB:ARDM) ("Aradigm") today announced it completed enrollment in its Phase 2 clinical trial of its inhaled liposomal ciprofloxacin in adult patients with non-cystic fibrosis bronchiectasis. The study was initiated in July 2008 in leading bronchiectasis centers in the United Kingdom and enrolled a total of 36 patients as planned. The subjects were randomized to two different dose levels of once-daily inhaled liposomal ciprofloxacin in a parallel design for a...

2008-09-18 15:00:38

Depomed, Inc. (NASDAQ: DEPO) today announced that president and chief executive officer, Carl A. Pelzel, will present on Tuesday, September 23, 2008 at 8:30 a.m. ET during the UBS Global Life Sciences Conference to be held in New York City. Interested parties can access a live, or archived, webcast of the presentation on the company's website at www.depomedinc.com. About Depomed Depomed, Inc. is a specialty pharmaceutical company with two approved products on the market and...

2008-08-30 09:00:20

By Jarzembowski, Jason A Young, Michael B * Context.-Nontuberculous mycobacteria include numerous acid- fast bacilli species, many of which have only recently been recognized as pathogenic. The diagnosis of mycobacterial disease is based on a combination of clinical features, microbiologic data, radiographic findings, and histopathologic studies. Objective.-To provide an overview of the clinical and pathologic aspects of nontuberculous mycobacteria infection, including diagnostic laboratory...

d9cba98a0079fb0777504cd1be9b50351
2008-08-02 13:46:21

Americans became fearful of anthrax in October of 2001, after the white powder killed five people and sickened 17 as it was sent in envelopes through the U.S. postal service. The deadly attacks created contamination scares throughout the country and forced the post office to alter its letter-handling procedures. The tragedy is now back in the news with the apparent suicide of biodefense researcher Bruce E. Ivins of the government labs at Fort Detrick, Maryland. At the time of his death,...

2008-08-02 12:00:11

By Randolphe Schmid Associated Press WASHINGTON -- Seven years ago, Americans learned to fear anthrax as a white powder in the mail that claimed lives, forced the post office to change the way it handles letters and sparked contamination scares across the country. The anthrax attacks have returned to the news after biodefense researcher Bruce E. Ivins of the government labs at Fort Detrick, Md., apparently committed suicide as prosecutors prepared to seek charges against him in the...


Word of the Day
out-herod
  • In the phrase to out-herod Herod, to be more violent than Herod (as represented in the old mystery plays); hence, to exceed in any excess of evil.
Herod refers to 'Herod the Great,' a Roman client king and 'a madman who murdered his own family and a great many rabbis.' According to the OED, the term is 'chiefly with allusion to Shakespeare's use' in Hamlet.
Related